ICNC Abstracts, ICNC 2018

Font Size: 
Pediatric anti-NMDA receptor encephalitis: experience of a tertiary care teaching center in North India
Biswaroop Chakrabarty, Prateek Kumar Panda, Prashant Jauhari, Vishal Sondhi, Rachana Dubey, Sheffali Gulati

Last modified: 2018-09-12



Anti-N-methyl-d-aspartate receptor (Anti-NMDAR) encephalitis is one of the commonest forms of autoimmune encephalitis and is emerging as a leading cause of acute to subacute encephalitis syndrome.

Methods: Clinical profile and outcome of children aged upto14 years with anti NMDAR encephalitis(by CSF anti NMDA receptor antibody positivity) between January 2013 and June 2018 in a north Indian tertiary care center were retrospectively reviewed.

Results: Out of 153 children with acute/subacute encephalitis syndrome, NMDA encephalitis was suspected in64 children (41%).  Of them, 19% children (n=30, 17 girls, median age 7 years, IQR 5-10 years) hadproven Anti-NMDAR encephalitis. Commonest clinical manifestations were neuropsychiatric (96%), extrapyramidal (86%), seizures(86 %%) and autonomic disturbances (60 %).

Sites affected predominantly on MRI brain were limbic region (13 %) and temporal lobe(10 %) whereascommonest EEG abnormality was generalized slowing (95%).

In the initial episode, 27 (90%) childrenresponded to concomitant IVIG and methyl prednisolone pulse therapy followed by oral steroid with tapering over 8 -12 weeks. However 3 children additionally required plasmapharesis, of which 2 also received rituximab. Seven (23%) had recurrences over (14 months, IQR 6-20 months), of which 5 responded favourably to IVIG and methylprednislone therapy, remaining 2 required plasmapheresis (1 required rituximabas well).None of the patients were positive on tumor screen.

Conclusion: Timely identification and early institution of immunotherapy is imperative for favorable long term outcome in children with suspected Anti NMDAR encephalitis.


NMDA, encephalitis, children

Conference registration is required in order to view papers.